Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Authors:
- Ryan N. SerioRSRyan N. Serio
- Armin SchebenASArmin Scheben
- Billy LuBLBilly Lu
- Domenic V. GargiuloDGDomenic V. Gargiulo
- Lucrezia PatrunoLPLucrezia Patruno
- Caroline L. BuckholtzCBCaroline L. Buckholtz
- Ryan J. ChaffeeRCRyan J. Chaffee
- Megan C. JibilianMJMegan C. Jibilian
- Steven G. PersaudSPSteven G. Persaud
- Stephen J. StaklinskiSSStephen J. Staklinski
- Rebecca HassettRHRebecca Hassett
- Lise M. BraultLBLise M. Brault
- 5 July 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (10) , 1990-2009
Abstract
The patterns by which primary tumors spread to metastatic sites remain poorly understood. Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model—EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes. To define migration histories between primary and metastatic sites, we used our EvoTraceR pipeline to track distinct tumor clones containing recordable barcodes. We detected widespread intratumoral heterogeneity from the primary tumor in metastatic seeding, with few clonal populations instigating most migration. Metastasis-to-metastasis seeding was uncommon, as most cells remained confined within the tissue. Migration patterns in our model were congruent with human prostate cancer seeding topologies. Our findings support the view of metastatic prostate cancer as a systemic disease driven by waves of aggressive clones expanding their niche, infrequently overcoming constraints that otherwise keep them confined in the primary or metastatic site. Significance: Defining the kinetics of prostate cancer metastasis is critical for developing novel therapeutic strategies. This study uses CRISPR/Cas9-based barcoding technology to accurately define tumor clonal patterns and routes of migration in a novel somatically engineered mouse model (EvoCaP) that recapitulates human prostate cancer using an in-house developed analytical pipeline (EvoTraceR).Keywords
All Related Versions
Funding Information
- National Cancer Institute (R01-CA272466)
- National Cancer Institute (NIH 2018 P50 CA)
- American Cancer Society (Research Scholar Grant)
- Department of Defense Education Activity (W81XWH-22-1-0068)
- National Institutes of Health (R35-GM127070)
- National Cancer Institute (T32CA203702)
- National Institutes of Health (5T32GM141949)
- National Institutes of Health (1T32GM141949)
- Starr Foundation (Centennial Scholarship)
- Cancer Research UK (22790)
- Fondazione AIRC per la ricerca sul cancro ETS (22790)
This publication has 72 references indexed in Scilit:
- Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settingsCancer Cell, 2021
- Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT statesCancer Cell, 2021
- CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer ModelingCell, 2014
- Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer MetastasisCell, 2014
- Distribution of metastatic sites in patients with prostate cancer: A population‐based analysisThe Prostate, 2013
- Prostate Epithelial Pten/TP53 Loss Leads to Transformation of Multipotential Progenitors and Epithelial to Mesenchymal TransitionThe American Journal of Pathology, 2011
- Detecting Mycoplasma Contamination in Cell Cultures by Polymerase Chain Reaction2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Tumor Self-Seeding by Circulating Cancer CellsCell, 2009
- Dichotomy of astrocytoma migration and proliferationInternational Journal of Cancer, 1996